11,617 Bristol Myers Squibb Company $BMY Shares Bought by Monument Capital Management

Posted by Francis Steltz on Oct 9th, 2026

Monument Capital Management grew its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 90.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,484 shares of the biopharmaceutical company’s stock after acquiring an additional 11,617 shares during the period. Monument Capital Management’s holdings in Bristol Myers Squibb were worth $1,528,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BMY. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $27,000. Addison Advisors LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $32,000. Bayban bought a new stake in Bristol Myers Squibb during the 4th quarter valued at $31,000. Groupe la Francaise lifted its holdings in shares of Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 501 shares during the period. Finally, Kilter Group LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Zenbexus delivered a major Phase 3 win. Bristol Myers said the iberdomide combination with daratumumab and dexamethasone produced superior progression-free survival versus standard care in relapsed and refractory multiple myeloma, reducing the risk of disease progression or death by 51%. The result strengthens Zenbexus’s potential as a growth product and supports the company’s oncology strategy. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
Positive Sentiment: Growth products may offset older-drug declines. Reblozyl continues to post strong growth, while a Camzyos label expansion could broaden the addressable market. Investors also continue to highlight BMY’s dividend, value characteristics and potential for another earnings beat. Reblozyl Growth Outlook
Neutral Sentiment: Analysts expect a favorable earnings setup, citing Bristol Myers’ history of exceeding estimates and current earnings trends. However, these reports are projections rather than new company guidance. Bristol Myers Earnings Outlook
Neutral Sentiment: Market commentary remains divided. Some coverage favors BMY over Pfizer because of its specialized oncology portfolio, while other reports describe the pullback as a value opportunity supported by the dividend.
Negative Sentiment: Analyst actions are a near-term headwind. Cantor Fitzgerald cut its price target to $53 and assigned a neutral rating, while Morgan Stanley issued a sell recommendation. These calls reinforce concerns about competition, debt and dependence on newer products to replace declining legacy revenue. Morgan Stanley Sell Rating

Analysts Set New Price Targets

Several brokerages have recently commented on BMY. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Royal Bank Of Canada raised their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, TD Cowen initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and a consensus price target of $66.72.

View Our Latest Stock Analysis on BMY

Bristol Myers Squibb Trading Down 0.3%

Shares of NYSE BMY opened at $59.51 on Friday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock has a market capitalization of $121.57 billion, a P/E ratio of 13.11, a price-to-earnings-growth ratio of 0.28 and a beta of 0.19. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The business has a fifty day moving average price of $64.27 and a 200 day moving average price of $60.28.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by company insiders.

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.